Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02251652 |
Recruitment Status :
Completed
First Posted : September 29, 2014
Results First Posted : April 26, 2017
Last Update Posted : April 26, 2017
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Actinic Keratoses | Drug: Ingenol Mebutate Procedure: Cryotherapy | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 16 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | An Investigator-Initiated Study to Assess the Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses (AK) on Dorsal Hands |
Study Start Date : | April 2013 |
Actual Primary Completion Date : | December 2014 |
Actual Study Completion Date : | August 2015 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Combination Therapy
Cryotherapy followed by Ingenol Mebutate Gel
|
Drug: Ingenol Mebutate
Ingenol mebutate 0.05% gel
Other Name: PEP005 Gel Procedure: Cryotherapy 1-2 sprays, 5 seconds each, with a 5 second interval |
Active Comparator: Cryotherapy Alone
Cryotherapy only
|
Procedure: Cryotherapy
1-2 sprays, 5 seconds each, with a 5 second interval |
- Safety of Combination Therapy vs Cryotherapy Alone [ Time Frame: Day 57 ]To evaluate the safety of cryotherapy plus ingenol mebutate on dorsal hands and compare it to the safety of cryotherapy alone looking at Adverse Events.
- Change in Number of All Actinic Keratoses [ Time Frame: Baseline and Day 57 ]To evaluate and compare the mean reduction in number of all AKs (hypertrophic and non-hypertrophic) on the dorsal hands of the combination cryotherapy- ingenol mebutate treated side vs. the cryotherapy alone side on Day 57 as compared to baseline
- Change in Actinic Keratoses by Anatomic Site [ Time Frame: Baseline and Day 57 ]To evaluate the number of AKs (both hypertrophic and non-hypertrophic) before therapy by anatomic site (dorsal hand) at Day 57 as compared to baseline

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Adults at least 18 years old.
- Subjects must be in good general health as confirmed by the medical history.
- Subjects must be able to read, sign, and understand the informed consent
- Prior to cryosurgery, subjects have at least 3 hypertrophic actinic keratoses on each dorsal hand.
- Subject must be willing to forego any other treatments on the dorsum of the hands, including tanning bed use and excessive sun exposure while in the study.
- Subject is willing and able to participate in the study as an outpatient, making frequent visits to the study center during the treatment and follow-up periods and to comply with all study requirements including concomitant medication and other treatment restrictions.
- If subject is a female of childbearing potential she must have a negative urine pregnancy test result prior to study treatment initiation and must agree to use an approved method of birth control while enrolled in the study.
Exclusion Criteria:
- Subjects with a history of melanoma anywhere on the body.
- Subjects with an unstable medical condition as deemed by the clinical investigator.
- Subjects with non-melanoma skin cancer on the dorsum of the hands.
- Subjects with any dermatologic disease in the treatment area that may be exacerbated by the treatment proposed or that might impair the evaluation of AKs.
- Subjects who have previously been treated with ingenol mebutate: on the dorsum of the hands in the past 6 months; or outside of the study area within the past 30 days.
- Women who are pregnant, lactating, or planning to become pregnant during the study period.
- Subjects who have experienced a clinically important medical event within 90 days of the visit (e.g., stroke, myocardial infarction, etc).
- Subjects who have active chemical dependency or alcoholism as assessed by the investigator.
- Subjects who have known allergies to any excipient in the study gel.
- Subjects who are currently participating in another clinical study or have completed another clinical study with an investigational drug or device on the study area within 30 days prior to study treatment initiation.
-
Subjects who have received any of the following within 90 days prior to study treatment initiation:
- interferon or interferon inducers
- cytotoxic drugs
- immunomodulators or immunosuppressive therapies (inhaled/ intranasal steroids are permitted)
- oral or parenteral corticosteroids
- topical corticosteroids if greater than 2 gm/day
- any dermatologic procedures or surgeries on the study area (including any AK treatments)
- Subjects who have used any topical prescription medications on the study area within 30 days prior to study treatment initiation.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02251652
United States, New York | |
Icahn School of Medicine at Mount Sinai | |
New York, New York, United States, 11370 |
Principal Investigator: | Gary Goldenberg, MD | Icahn School of Medicine at Mount Sinai |
Responsible Party: | Gary Goldenberg, Assistant Professor, Icahn School of Medicine at Mount Sinai |
ClinicalTrials.gov Identifier: | NCT02251652 |
Other Study ID Numbers: |
GCO 13-0142 |
First Posted: | September 29, 2014 Key Record Dates |
Results First Posted: | April 26, 2017 |
Last Update Posted: | April 26, 2017 |
Last Verified: | March 2017 |
Actinic |
Keratosis, Actinic Keratosis Skin Diseases Precancerous Conditions Neoplasms |